Novel panel of protein biomarkers to predict response to bortezomib-containing induction regimens in multiple myeloma patients

BACKGROUND: Multiple myeloma (MM) is a complex heterogeneous disease. Various risk stratification models have been recommended including cytogenetic and FISH analysis to identify high-risk patients who may benefit from novel treatments, but such facilities are not widely available. The International...

Descripción completa

Detalles Bibliográficos
Autores principales: Ting, Kay Reen, Henry, Michael, Meiller, Justine, Larkin, Annemarie, Clynes, Martin, Meleady, Paula, Bazou, Despina, Dowling, Paul, O'Gorman, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502697/
https://www.ncbi.nlm.nih.gov/pubmed/28725572
http://dx.doi.org/10.1016/j.bbacli.2017.05.003

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502697/
https://www.ncbi.nlm.nih.gov/pubmed/28725572
http://dx.doi.org/10.1016/j.bbacli.2017.05.003

Ejemplares similares